Described herein are compounds and compositions for treating glaucoma and/or reducing introcular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

“PHARMACEUTICAL COMBINATION CONTAINING AN ANALGESIC AGENT AND AN ANTISPASMODIC AGENT”, whose analgesic agent is the Ketorolac Tromethamine, which is physically isolated from the antispasmodic agent and whose antispasmodic active ingredient, in combination with the analgesic agent Ketorolac Tromethamine, is Hyoscine, Pargeverine, Tolterodine, Mebeverine or Papaverine. Both the analgesic agent Ketorolac Tromethamine and the antispasmodic agent are combined in separate and immediate release form. The analgesic agent Ketorolac Tromethamine can also be found in the present combination in separate and immediate release form, while the combined antispasmodic agent is presented in equally separate, but programmed release form. The active ingredient Ketorolac Tromethamine is in a ratio between 2.5% and 20% by weight and the antispasmodic active ingredient is in a ratio between 2.5% and 20% by weight.

“PHARMACEUTICAL COMBINATION CONTAINING AN ANALGESIC AGENT AND AN ANTISPASMODIC AGENT”, whose analgesic agent is the Ketorolac Tromethamine, which is physically isolated from the antispasmodic agent and whose antispasmodic active ingredient, in combination with the analgesic agent Ketorolac Tromethamine, is Hyoscine, Pargeverine, Tolterodine, Mebeverine or Papaverine. Both the analgesic agent Ketorolac Tromethamine and the antispasmodic agent are combined in separate and immediate release form. The analgesic agent Ketorolac Tromethamine can also be found in the present combination in separate and immediate release form, while the combined antispasmodic agent is presented in equally separate, but programmed release form. The active ingredient Ketorolac Tromethamine is in a ratio between 2.5% and 20% by weight and the antispasmodic active ingredient is in a ratio between 2.5% and 20% by weight.

“PHARMACEUTICAL COMBINATION CONTAINING AN ANALGESIC AGENT AND AN ANTISPASMODIC AGENT”, whose analgesic agent is the Ketorolac Tromethamine, which is physically isolated from the antispasmodic agent and whose antispasmodic active ingredient, in combination with the analgesic agent Ketorolac Tromethamine, is Hyoscine, Pargeverine, Tolterodine, Mebeverine or Papaverine. Both the analgesic agent Ketorolac Tromethamine and the antispasmodic agent are combined in separate and immediate release form. The analgesic agent Ketorolac Tromethamine can also be found in the present combination in separate and immediate release form, while the combined antispasmodic agent is presented in equally separate, but programmed release form. The active ingredient Ketorolac Tromethamine is in a ratio between 2.5% and 20% by weight and the antispasmodic active ingredient is in a ratio between 2.5% and 20% by weight.

The present disclosure relates generally to derivatives of capsazepine and methods of use thereof In some aspects, the present disclosure relates to using capsazepine derivatives to treat cancer or other hyperproliferative diseases. In some aspects of the present disclosure, the disclosure provides capsazepine derivatives which may be useful in the treatment of cancer. Such cancers that the compounds may be used to treating include but are not limited to breast, cervical, oral, head, neck, or prostate cancer. In some aspects, the compounds may be useful in treating a tumor by direct injection of the compound into the tumor, particularly an oral tumor. In other aspects, the compounds are administered systemically. The compounds of the present disclosure may also be used to treat the pain associated with a tumor for which it is being administered.

The present disclosure relates generally to derivatives of capsazepine and methods of use thereof In some aspects, the present disclosure relates to using capsazepine derivatives to treat cancer or other hyperproliferative diseases. In some aspects of the present disclosure, the disclosure provides capsazepine derivatives which may be useful in the treatment of cancer. Such cancers that the compounds may be used to treating include but are not limited to breast, cervical, oral, head, neck, or prostate cancer. In some aspects, the compounds may be useful in treating a tumor by direct injection of the compound into the tumor, particularly an oral tumor. In other aspects, the compounds are administered systemically. The compounds of the present disclosure may also be used to treat the pain associated with a tumor for which it is being administered.

The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.

The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. ##STR00001##

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. ##STR00001##